Amferia kills bacteria

About

Amferia is a Swedish medical device company founded in 2018 and based in Mölndal, Gothenburg. The company focuses on developing antimicrobial peptide-based products to address bacterial infections, including those caused by antibiotic-resistant bacteria. Amferia was established by three PhD researchers from Chalmers University of Technology, who combined their expertise to create innovative antimicrobial materials. The company's core technology involves engineered antimicrobial peptides derived from the mammalian immune system. These peptides can effectively kill bacteria while preserving human cells. Amferia has developed a unique amphiphilic hydrogel material that protects these peptides, making them suitable for various medical applications. Their product range includes wound care dressings, pre-surgery antimicrobial patches, antimicrobial sprays, and veterinary applications for treating post-surgical wounds in animals. Clinical trials have shown that their wound dressings can achieve a 99.9% reduction in bacteria. Amferia primarily targets the healthcare industry, serving both human and animal health markets. The company is currently introducing its products in several European countries and has garnered significant interest internationally, particularly in Europe, the USA, and Asia.